Anti-Human/Mouse GRP78 Antibody (N88) 

Anti-Human/Mouse GRP78 Antibody (N88) is an anti-human/mouse GRP78 IgG1 monoclonal antibody. Anti-Human/Mouse GRP78 Antibody (N88) can activate the Akt signaling pathway. Anti-Human/Mouse GRP78 Antibody (N88) can inhibit the expression of inflammatory factors and plasminogen activator inhibitors induced by TLR agonists. Anti-Human/Mouse GRP78 Antibody (N88) can be used for research on inflammation conditions. Anti-Human/Mouse GRP78 Antibody (N88) can be used for immunoprecipitation^[1][2].

Mouse IgG1 kappa

Mouse IgG1 kappa, Isotype Control

Human/Mouse

Anti-Human/Mouse GRP78 Antibody (N88) (1 μg/mL, 1 h or 6 h) significantly inhibits the expression of TNF α, IL-6, IL-1β, CCL2, CCL3, and CCL4 induced by LPS (HY-D1056) and reduces the phosphorylation of IκBα in bone marrow-derived macrophages (BMDMs)^[1].
Anti-Human/Mouse GRP78 Antibody (N88) (1 μg/mL, 1 h or 6 h) widely inhibits the inflammatory response and inhibits the expression of PAI1 and PAI2 induced by multiple TLR agonists (Lipoteichoic acid (LTA) (HY-N9481), Imiquimod (IMQ) (HY-B0180), or ODN 1826 (HY-146245)) in BMDMs^[1].
Anti-Human/Mouse GRP78 Antibody (N88) (1 μg/mL, 15 min) activates Akt phosphorylation in a dose-dependent manner in B16F1 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Human/Mouse GRP78 Antibody (N88) (200 μg, i.p., once every 14 days) accelerates tumor growth and shortens survival time in female C57BL/6 mice bearing B16F1 tumors^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

14828  [NCBI]

P20029

in vivo administration; Functional assays

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

[Anti-Human/Mouse GRP78 Antibody (N88)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gunner CB, et al. An antibody that targets cell-surface glucose-regulated protein-78 inhibits expression of inflammatory cytokines and plasminogen activator inhibitors by macrophages. J Cell Biochem. 2023 May;124(5):743-752.  [Content Brief]

  [2]. Trink J, et al. Integrin β1/Cell Surface GRP78 Complex Regulates TGFβ1 and Its Profibrotic Effects in Response to High Glucose. Biomedicines. 2022 Sep 10;10(9):2247.  [Content Brief]

  [3]. de Ridder GG, et al. A murine monoclonal antibody directed against the carboxyl-terminal domain of GRP78 suppresses melanoma growth in mice. Melanoma Res. 2012 Jun;22(3):225-35.  [Content Brief]